CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas

Published:2020-08-13 Issue: Volume:11 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Cassandri Matteo,Fioravanti Rossella,Pomella Silvia,Valente Sergio,Rotili Dante,Del Baldo Giada,De Angelis Biagio,Rota Rossella,Mai Antonello

Funder

Associazione Italiana per la Ricerca sul Cancro

Ministero della Salute

Ministero dell’Istruzione, dell’Università e della Ricerca

Sapienza Università di Roma

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference96 articles.

1. Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans;Adelman;Nat. Rev. Genet.,2012

2. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor;Albert;Br. J. Pharmacol.,2014

3. New strategies in ewing sarcoma: lost in translation;Arnaldez;Clin. Cancer Res.,2014

4. CDK9: a signaling hub for transcriptional control;Bacon;Transcription,2019

5. NF-κB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II;Barboric;Mol. Cell,2001

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New strategies in soft tissue sarcoma treatment;Journal of Hematology & Oncology;2024-09-02

2. Docking and Molecular Dynamics Studies on Anticancer Activities of Flavonoids as Inhibitors of CDK2 and CDK9;Medicinal Chemistry;2024-08-28

3. Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma;Biochemical Pharmacology;2024-08

4. Uncovering potential CDK9 inhibitors from natural compound databases through docking-based virtual screening and MD simulations;Journal of Molecular Modeling;2024-07-16

5. Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future;Medicinal Research Reviews;2024-06-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3